

**Table S1. Baseline characteristics of CVD patients at study entry stratified by presence of acute SARS-CoV-2 infection**

Parameters	All patients (n=57)	CVD (n=20)	CVD-SARS-CoV- 2 (n=37)	p-Value
Clinical characteristics				
Age (y)	68 (58-80)	67 (59-78)	69 (57-81)	0.647
Male	29 (50.9)	9 (45)	20 (54.1)	0.514
BMI (kg/m²)	26.6 (24.9-29.6)	25 (23.3-27.3)	27.4 (25.1-31.4)	0.091
ICU admission	11 (19.3)	0 (0)	11 (29.7)	<b>0.007</b>
ARDS				
- mild	19 (33.3)	0 (0)	19 (51.4)	<b>&lt;0.001</b>
- moderate	8 (14)	0 (0)	8 (21.6)	
- severe	5 (8.7)	0 (0)	5 (13.5)	
Horovitz Index				
- HI > 300 mmHg	33 (57.9)	20 (100)	13 (35.1)	<b>&lt;0.001</b>
- HI 201 - 300 mmHg	4 (7)	0 (0)	4 (10.8)	
- HI 101 - 200 mmHg	11 (19.3)	0 (0)	11 (29.7)	
- HI ≤ 100 mmHg	9 (15.8)	0 (0)	9 (24.3)	
High flow O <sub>2</sub> Therapy	5 (8.1)	0 (0)	5 (13.5)	
Mechanical ventilation	8 (14)	0 (0)	8 (21.6)	
Vasopressor	6 (10.5)	0 (0)	6 (16.2)	
Lymphocyte count at Nadir (1000/μl)	0.8 (0.6-1.2)		0.8 (0.6-1.2)	
Bacterial Co-Infection	14 (24.6)	0 (0)	14 (37.8)	<b>0.025</b>
Dialysis	5 (8.1)	0 (0)	5 (13.5)	
Acute hepatic injury	4 (7)	0 (0)	4 (10.8)	
Symptoms on admission				
Cough	18 (31.6)	0 (0)	18 (48.6)	<b>&lt;0.001</b>
Dyspnea	18 (31.6)	0 (0)	18 (48.6)	<b>&lt;0.001</b>
Fever	20 (35.1)	0 (0)	20 (54.1)	<b>&lt;0.001</b>
Cardiovascular risk factors				
Arterial hypertension	42 (73.7)	15 (75)	27 (73)	0.868
Dyslipidemia	29 (50.9)	9 (45)	20 (54.1)	0.449
Diabetes mellitus	10 (17.5)	2 (10)	8 (14.)	0.271